Eledon Pharmaceuticals, Inc. (ELDN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | CEO & Non Independent Director | 1.07M | -- | 1972 |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer & Non Independent Director | 784.13k | -- | 1966 |
| Mr. Paul Sean Little | Chief Financial Officer | 724.49k | -- | 1965 |
| Mr. John Herberger | Vice President of Technical Operations | -- | -- | -- |
| Mr. Bryan E. Smith J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 377.14k | -- | 1980 |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer | -- | -- | -- |
| Dr. Eliezer Katz F.A.C.S., FACS, M.D. | Chief Medical Officer | -- | -- | -- |
| Ms. Marina Escudero | VP & Head of Clinical Operations | -- | -- | -- |
Eledon Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Corporate Governance
Upcoming Events
August 18, 2025 at 8:00 PM UTC - August 22, 2025 at 8:00 PM UTC
Eledon Pharmaceuticals, Inc. Earnings Date